AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...